JP2022541277A5 - - Google Patents

Info

Publication number
JP2022541277A5
JP2022541277A5 JP2022503457A JP2022503457A JP2022541277A5 JP 2022541277 A5 JP2022541277 A5 JP 2022541277A5 JP 2022503457 A JP2022503457 A JP 2022503457A JP 2022503457 A JP2022503457 A JP 2022503457A JP 2022541277 A5 JP2022541277 A5 JP 2022541277A5
Authority
JP
Japan
Prior art keywords
ether
group
alkyl
range
ether lipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022503457A
Other languages
English (en)
Japanese (ja)
Other versions
JP7890196B2 (ja
JP2022541277A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2020/050742 external-priority patent/WO2021007623A1/en
Publication of JP2022541277A publication Critical patent/JP2022541277A/ja
Publication of JP2022541277A5 publication Critical patent/JP2022541277A5/ja
Application granted granted Critical
Publication of JP7890196B2 publication Critical patent/JP7890196B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022503457A 2019-07-17 2020-07-17 ヒト対象の組織におけるエーテル脂質分子の混合物を維持または調節するための組成物 Active JP7890196B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2019902527 2019-07-17
AU2019902527A AU2019902527A0 (en) 2019-07-17 Compositions and methods of use
PCT/AU2020/050742 WO2021007623A1 (en) 2019-07-17 2020-07-17 Compositions for maintaining or modulating mixtures of ether lipid molecules in a tissue of a human subject

Publications (3)

Publication Number Publication Date
JP2022541277A JP2022541277A (ja) 2022-09-22
JP2022541277A5 true JP2022541277A5 (cg-RX-API-DMAC10.html) 2023-07-21
JP7890196B2 JP7890196B2 (ja) 2026-07-14

Family

ID=74209622

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022503457A Active JP7890196B2 (ja) 2019-07-17 2020-07-17 ヒト対象の組織におけるエーテル脂質分子の混合物を維持または調節するための組成物

Country Status (10)

Country Link
US (1) US20220257616A1 (cg-RX-API-DMAC10.html)
EP (1) EP3999044A4 (cg-RX-API-DMAC10.html)
JP (1) JP7890196B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220047775A (cg-RX-API-DMAC10.html)
CN (2) CN120360984A (cg-RX-API-DMAC10.html)
BR (1) BR112022000814A2 (cg-RX-API-DMAC10.html)
CA (1) CA3147249A1 (cg-RX-API-DMAC10.html)
IL (1) IL289859A (cg-RX-API-DMAC10.html)
MX (1) MX2022000664A (cg-RX-API-DMAC10.html)
WO (1) WO2021007623A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115236170B (zh) * 2022-07-25 2024-11-26 清华大学 基于毛细管电泳的脂质组分析系统及其应用和脂质组的分析方法
WO2024148052A1 (en) 2023-01-03 2024-07-11 Baker Heart and Diabetes Institute Ether of phosphatidylcholine and phosphatidylethanolamine, their lyso-forms and mixture thereof for use in the treatment of treatment of a disease or disorder caused by a deficiency in plasmalogens
EP4661856A1 (en) * 2023-02-10 2025-12-17 Baker Heart and Diabetes Institute Plasmalogen modulation of immune cells
WO2026008605A2 (en) 2024-07-01 2026-01-08 Pelagic Ai Limited Chemical synthesis of bioactive precursors to plasmalogens
WO2026008716A1 (en) 2024-07-02 2026-01-08 Baker Heart and Diabetes Institute Methods of use for plasmalogen precursors in treating plasmalogen-associated diseases

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1029610A (en) 1965-04-08 1966-05-18 Shell Int Research Improvements in or relating to ethers
US4046914A (en) 1966-12-16 1977-09-06 Astra Nutrition Ab Therapeutically active substituted saturated and mono-and polyunsaturated alkyl-glycerylethers
JPS56133281A (en) 1980-03-21 1981-10-19 Kao Corp Preparation of glyceryl ether
US4613621A (en) 1981-09-18 1986-09-23 Hoerrmann Wilhelm Fatty aldehydes and acids in the treatment of neurological and inflammatory diseases
US4595681A (en) * 1984-10-26 1986-06-17 The United States Of America As Represented By The United States Department Of Energy Antihypertensive neutral lipid
SE8800182L (sv) 1988-01-21 1989-07-22 Kaernerud Lars Haelsoprod Anvaendning av alkylglycerol foer framstaellning av ett laekemedel
ATE318832T1 (de) 1990-06-11 2006-03-15 Gilead Sciences Inc Verfahren zur vervendung von nukleinsäureliganden
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5840867A (en) 1991-02-21 1998-11-24 Gilead Sciences, Inc. Aptamer analogs specific for biomolecules
US6121245A (en) 1997-01-29 2000-09-19 Firshein; Richard N. Method of treating cancer using alkylglycerols in conjunction with chemotherapy
SE9701912D0 (sv) 1997-05-22 1997-05-22 Interhealth Ab Pharmaceutical composition and use thereof
US6242246B1 (en) 1997-12-15 2001-06-05 Somalogic, Inc. Nucleic acid ligand diagnostic Biochip
US20070191495A1 (en) 2004-01-16 2007-08-16 Fuji Oil Company, Limited Lipase inhibitor
FR2874156B1 (fr) 2004-08-13 2007-04-06 Univ Rennes 1 Etablissement Pu Complement alimentaire pour animaux d'elevage et procede de mise en oeuvre de celui-ci
US20090131368A1 (en) 2006-07-19 2009-05-21 Su Chen Mixtures of and methods of use for polyunsaturated fatty acid-containing phospholipids and alkyl ether phospholipids species
EP2064544A1 (en) 2006-09-14 2009-06-03 Zora Biosciences OY Biofluid metabolite profiling as a tool for early prediction of autoimmunity and type 1 diabetes risk
WO2009050692A2 (en) * 2007-10-16 2009-04-23 Vascular Biogenics Ltd. Platelet-activating factor (paf) analogs and uses thereof
US8975299B2 (en) 2007-11-01 2015-03-10 Enzymotec Ltd. Lipid mixture for infant nutrition
EP2403491A2 (en) 2009-03-04 2012-01-11 Nestec S.A. Alkylglycerols and alkoxyglycerols for increasing endogenous plasmalogen levels in mammals
FR2945951B1 (fr) 2009-05-26 2012-07-13 Polaris Composition d'akg et son utilisation pour la fabrication d'un medicament.
DE102009022907A1 (de) * 2009-05-27 2010-12-09 Kdg Mediatech Ag Optischer Datenträger
EP2309276A1 (en) 2009-09-22 2011-04-13 One Way Liver Genomics, S.L. Method for the diagnosis of non-alcoholic steatohepatitis based on a metabolomic profile
KR101787618B1 (ko) 2010-09-24 2017-10-18 후지노 브레인 리서치 가부시키가이샤 항중추신경계 염증제
JP5709304B2 (ja) 2011-01-06 2015-04-30 日光ケミカルズ株式会社 水中油型乳化化粧料
CA2812178C (en) 2011-11-17 2014-11-04 Phenomenome Discoveries Inc. Methods for the synthesis of plasmalogens and plasmalogen derivatives, and therapeutic uses thereof
EP2810079A4 (en) * 2012-01-31 2015-08-05 Teknologian Tutkimuskeskus Vtt Oy PROCESS FOR DETERMINING THE LIVERY QUANTITY OF LIQUID AND METHOD FOR DIAGNOSIS OF NAFLD
KR101639128B1 (ko) 2013-10-29 2016-07-13 울산대학교 산학협력단 플라스마로젠 전구체, 플라스마로젠 또는 플라스마로젠 유사체를 유효성분으로 함유하는 간질환 예방 또는 치료용 약학조성물
WO2015196250A1 (en) 2014-06-27 2015-12-30 Commonwealth Scientific And Industrial Research Organisation Lipid comprising docosapentaenoic acid
WO2016041013A1 (en) 2014-09-16 2016-03-24 Baker Idi Heart And Diabetes Institute Holdings Limited Glycerolipids and uses therefor
CN107080249A (zh) 2016-06-30 2017-08-22 健糖（北京）健康管理有限公司 一种供糖尿病人群食用的配方食品及其制备工艺

Similar Documents

Publication Publication Date Title
KR101468191B1 (ko) 인지 기능의 개선을 위한 글라이세로인지질
RU2014101211A (ru) Влияние на метаболический импринтинг специально разработанного липидного компонента
Burdge α‐linolenic acid interconversion is sufficient as a source of longer chain ω‐3 polyunsaturated fatty acids in humans: An opinion
BRPI0708378A2 (pt) uso de dha e ara na preparação de uma composição para prevenção ou tratamento de obesidade
CN1367816A (zh) 油脂组合物
JP2022541277A (ja) ヒト対象の組織におけるエーテル脂質分子の混合物を維持または調節するための組成物
Koletzko et al. Dietary long-chain polyunsaturated fatty acid supplementation in infants with phenylketonuria: a randomized controlled trial
CN102413822A (zh) 提高哺乳动物中内源性缩醛磷脂水平的方法
US10894056B2 (en) Phospholipid preparations for the improvement of sleep
CN120659550A (zh) 具有改善的抗离析性的营养组合物
KR101254353B1 (ko) 분말 조성물
JP2015091855A (ja) アテローム性動脈硬化症の治療のための循環酸化低密度リポタンパク質‐ベータ‐２‐糖タンパク質１複合体を減少させる方法
JP2001247473A (ja) インスリン抵抗性改善剤
CN116981454A (zh) 血中癸酸浓度的上升方法、血中癸酸浓度上升剂、医药组合物、食品组合物
CN107072277A (zh) 用于改善行为的脂质组合物
Lee et al. Impact of high‐intensity ultrasound on physical properties and degree of oxidation of lipase modified menhaden oil with caprylic acid and/or stearic acid
Montague The physiology of obesity.
WO2007129439A1 (ja) 食後血中インスリン上昇抑制剤
JP6291058B2 (ja) セリングリセロリン脂質調製物及び発作の治療方法
Bruder et al. Lipid and fatty acid profiles in the brain, liver, and stomach contents of neonatal rats: effects of hypoxia
RU2402928C1 (ru) Состав безлактозной смеси для диетического питания детей с галактоземией
KR102365334B1 (ko) 포스파티딜세린 분말을 함유한 영양 조성물
JP6153241B2 (ja) 肝機能障害予防改善剤
Matsui et al. Effects of taurine intake on serum lipids in young women
JP7157743B2 (ja) ケトン体生成促進剤